Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Mycoplasma Testing Market Size

ID: MRFR//5312-HCR | 100 Pages | Author: Rahul Gotadki| May 2024

The mycoplasma testing market is essentially affected by the development of the biopharmaceutical business. As biopharmaceutical organizations expand their development of biologics, cell-based treatments, and immunizations, the requirement for thorough mycoplasma testing to guarantee item wellbeing drives market demand.
Mycoplasma infection poses a significant risk as cell culture usage for research and development expand. The demand for trustworthy and delicate testing procedures to detect and prevent contamination by mycoplasma in cell cultures drives the mycoplasma testing marketplace forward.
The worldwide reach of the biotechnology industry encourages more cross-line collaboration and interchange of biopharmaceutical goods. Mycoplasma testing becomes urgent in guaranteeing the wellbeing and nature of these items, encouraging market development.
Developing research and advancement exercises in the existence sciences area add to the demand for mycoplasma testing. Labs and research organizations directing cell-based examinations perceive the requirement for solid testing techniques, driving the market forward.
The pervasiveness of mycoplasma contamination in cell cultures keeps on rising, requiring hearty testing arrangements. The mycoplasma testing market is driven by the rising attention to the effect of contamination on research honesty and item wellbeing.
The extension of biomanufacturing offices internationally adds to the mycoplasma testing market's development. As creation limits increment, the demand for effective and versatile mycoplasma testing arrangements rises to guarantee the nature of biopharmaceutical items.
The expense viability of mycoplasma testing arrangements is a critical element impacting market elements. Reasonable and productive testing strategies appeal to a more extensive scope of clients, including more modest biotechnology organizations and research labs.
The accentuation on preventive estimates in cell culture works on, including routine mycoplasma testing, is a market driver. Proactive testing as a component of good cell culture rehearses limits the gamble of mycoplasma contamination, impacting the market decidedly.
Developing markets with developing biopharmaceutical areas present undiscovered open doors for the mycoplasma testing market. As mindfulness expansions in these districts, the demand for mycoplasma testing arrangements is supposed to rise, driving market extension.

Mycoplasma Testing Market Overview:


The mycoplasma testing market size was valued USD 802 million in 2021 and is expected to reach USD 2.31 billion by 2030 at 14.1% CAGR during the forecast period 2022-2030. Mycoplasma testing is used to detect contamination in a biological sample. Increasing R&D costs and new product releases are projected to drive the market growth of the mycoplasma testing. However, the availability of alternative conventional methods will impede the market growth of the mycoplasma testing over the projection period. The market of mycoplasma testing is divided into three categories: product, technique, and application. The market is divided into three categories: kits and reagents, instruments, and services. In 2017, the kits and reagents category is predicted to account for the greatest proportion of the market.


Agathos Biologics has offered analytical testing services to life science researchers since April 2023. Agathos exclusively uses QIAcuity instruments and QIAGEN-developed assays. Moreover, Agathos has collaborated with QIAGEN to perform mycoplasma as well as recombinant adeno-associated viral vector (rAAV) assay testing and validation.


Thermo Fisher Scientific, Inc. launched the TrueMark STI Select Panel in February 2023. It is meant to detect the four most common STIs with only a single-panel application. The panel can be used to detect Chlamydia trachomatis and Mycoplasma genitalium by means of polymerase chain reaction.


As an example, SwiftDx brought to market a new mycoplasma detection kit in February 2023. The newly introduced SwiftDx Mycoplasma Detection Kit uses the Lateral Flow test for fast and easy detection of mycoplasma contaminants.


Merck KGaA spent over $427.3m (€399m) on its Life Science Business’s R&D facilities in December 2022. This investment will help companies develop new, innovative diagnostic technologies, including those that detect mycoplasmas, leading to more accurate, sensitive and affordable tests for these diseases, hence increasing its market penetration.


Abbott received approval from the United States Food and Drug Administration on Alinity m STI Assay in May 2022. The test can concurrently identify or differentiate four common STDs like MG (Mycoplasma genitalium).


Performer Availability Screening Service, Inc.(PASS) has partnered with Spankchain in April 2022 to launch an initiative that screens and treats Las Vegas performers who have Mycoplasma genitalium until one thousand performers are reached.


For instance, Fujifilm is investing approximately USD 76 million in Massachusetts in January 2021 for advanced research and development in cell and gene therapy, gene editing, immunotherapy as well as biotechnology.


In July 2020, Roche Diagnostics introduced Cobas 6800 which is an automatic system in India.


Mycoplasma testing is expected to expand due to rising R&D expenditures and the introduction of new products. However, competition from more established technologies will slow the mycoplasma testing market's expansion throughout the forecast period. With better healthcare infrastructure, more unmet healthcare requirements, and more mycoplasma contamination, emerging markets are likely to fuel the expansion of the mycoplasma testing market share. The testing of biologics and vaccines for mycoplasma contamination is also required by recommendations and rules published by regulatory organizations including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Because of this, mycoplasma testing has become more important in the biopharmaceutical sector.


The expansion of the mycoplasma testing market is being fueled by technical developments such as the creation of quicker and more accurate mycoplasma testing methods and devices. In addition, the demand for biologics and biosimilars is rising, which is fueling market expansion. Biologics and biosimilars are susceptible to mycoplasma infection during production, which poses hazards to product quality, effectiveness, and patient safety. Mycoplasma testing solutions are becoming increasingly important as the need for biologics and biosimilars develops, driving the industry forward. 


In April 2023:Agathos Biologics, a frontrunner in the biotech industry, said it will begin providing cutting-edge analytical testing to the life sciences. Their expert staff uses cutting-edge technology to provide unrivaled precision in nucleic acid measurement and cellular analysis, with a particular emphasis on high-content imaging and digital PCR. Agathos relied only on QIAcuity instruments and tests from QIAGEN, and the two companies worked together to validate mycoplasma and rAAV assays.


In December 2022:Pictor, a New Zealand (NZ) startup with offices in the US and India, announced a funding round to advance its Human Health and Animal Health product pipelines and expand into new markets in Australia/New Zealand, the US, and Europe. In light of the recent success of the PictArray SARS-CoV-2 IgG Antibody Test, distributed by Rako Science in New Zealand and major partners in the United States, this development comes as no surprise. To better manage dairy and beef herds in New Zealand and throughout the world, the firm will introduce its PictArray Mycoplasma bovis and Johne's disease tests in the second quarter of 2023.


Key players:


Some of the key players in the mycoplasma testing market are:



  • Charles River Laboratories

  • Inc., Merck KGaA, 

  • Lonza Group Ltd

  • Roche Diagnostics, 

  • SGS S.A., 

  • American Type Culture Collection, 

  • Invivogen, 

  • Wuxi Apptec, 

  • Thermo Fisher Scientific Inc., 

  • Promocell GmbH


Mycoplasma Testing Market Segment Insights:


The mycoplasma testing market has been segmented into product, Technique, and application.


Based on product, market segmented into kits & reagents, instruments, and services. The kits & reagents segment is expected to account for the largest share segment of the market in 2017.


Based on Technique, market segmented into DNA Stain, Enzyme-based, PCR, ELISA, Direct Assay, Indirect Assay, Others.


Based on application, market segmented into cell line and cell therapy testing, virus testing, row material testing, lot release testing, and others.


Based on end user, market segmented into pharmaceutical and biological manufacturing, contract research organizations, cell banks, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The mycoplasma testing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European market of mycoplasma testing has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.


The mycoplasma testing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market for mycoplasma testing in the Middle East & Africa has been segmented into the Middle East and Africa.


April 2023:Polymerase chain reaction (PCR) research use only test designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium in one test; includes RNase P as a human internal control; released by Thermo Fisher Scientific in February 2023. Rather of having laboratories do separate tests for each of the four most prevalent STIs, this solution can do so on a single panel. Researchers will be able to detect these sexually transmitted pathogenic germs more quickly and accurately thanks to this panel, which will aid in the development of future testing protocols and therapies.


Regional Market Summary


Geographically, the Americas is anticipated to dominate the mycoplasma testing market owing to a well-established player and increasing R&D expenses.


Europe is expected to hold the second largest position in the market of mycoplasma testing. The market growth in this region is attributed to the growth in pharmaceutical and medical devices industry.


The mycoplasma testing market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increasing adoption of these products.


The Middle East & Africa has the least share of the market.


Mycoplasma Testing Market Segmentation


Mycoplasma Testing Product Outlook



  • Kits & Reagents

  • Instruments

  • Services


Mycoplasma Testing Technique Outlook



  • DNA Stain

  • Enzyme-based

  • PCR

  • ELISA

  • Direct Assay

  • Indirect Assay

  • Others


Mycoplasma Testing Application Outlook



  • Cell Line and Cell Therapy Testing

  • Virus Testing

  • Row Material Testing

  • Lot Release Testing

  • Others


Mycoplasma Testing End User Outlook



  • Pharmaceutical and Biological Manufacturing

  • Contract Research Organizations

  • Cell Banks

  • Others


Mycoplasma Testing Region Outlook



  • Americas

    • North America

      • US

      • Canada



    • South America



  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe



  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Middle East & Africa

    • Middle East

    • Africa




The report for Mycoplasma Testing Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.


Recent Development


Lonza Group Ltd (Lonza) is a corporation that provides contract manufacturing and development solutions. It provides commercial mammalian and microbial production, clinical development, and manufacturing services. It also provides active pharmaceutical components with high potential, cell and gene therapy capabilities, sophisticated intermediates, oral medication product development services, cell culture models, genome editing, endotoxin products, and research media and testing goods. Lonza offers health and well-being solutions, microbiological and hygiene management, composites, and material protection. The corporation has production and research and development centers throughout Asia, Europe, and the Americas. Lonza is based in Basel, Switzerland.


The American Type Culture Collection (ATCC) is an important medical research resource. It is the world's foremost storehouse of biological cultures. Through in-house initiatives and collaborative collaborations, the ATCC conducts research to improve the propagation, preservation, categorization, and characterization of cultures, as well as to generate new and improved culture products. The ATCC was founded in 1925 and is presently located in Manassas, Virginia.Intended Audience



  • Mycoplasma testing products Manufacturers and vendors

  • Mycoplasma testing service providers

  • Pharmaceutical and Biotech companies

  • Contract research organization

  • Various research and consulting firms

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.